Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib + docetaxel + trastuzumab in first-line HER2-positive advanced breast cancer
2006-001151-35Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib, docetaxel and trastuzumab in breast cancer, sponsored by Pfizer. Primary endpoint: Safety profile. Started Sep 2006; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-001151-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001151-35.